Teva pleased to agree $225 million settlement in historic Barr case

30 January 2017
drugs_pills_tablets_big

Teva Pharmaceutical Industries (NYSE: TEVA) is to pay $225 million to settle a pay-for-delay case dating back to the 1990s.

The case relates to allegations that Barr Pharmaceuticals, which has since been bought by the Israeli generics giant for nearly $9 billion, was paid $398 million by Bayer (BAYN: DE) not to sell a generic of the German company’s antibiotic Cipro (ciprofloxacin).

Bayer had previously sued Barr, arguing that its generic version would infringe a patent, leading to the settlement between the companies. A group of American activists who bought Cipro, however, said that the settlement violated antitrust law, driving up prices. The case began in 2000 but only now has Teva reached a final settlement with the California Supreme Court.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics